A healthcare worker is seen preparing doses of the AstraZeneca Covid-19 vaccine at a vaccine hub in Rome in June 2021. The company has announced the withdrawal of its highly successful coronavirus vaccine due to declining demand, citing the availability of new vaccines on the market.
Since January 4, 2021, over 3 billion doses of Vaxzevria, which was developed in partnership with the University of Oxford, have been widely administered worldwide. However, despite its global reach, AstraZeneca has stated that the vaccine has not generated revenue since April 2023. The decline in demand for Vaxzevria has been attributed to the surplus of new Covid-19 vaccines available.
In response to this news, AstraZeneca has ceased manufacturing and supplying the product and initiated the withdrawal of marketing authorizations for Vaxzevria within Europe. The European Medicines Agency (EMA) has also announced the withdrawal of Vaxzevria’s marketing authorization in EU countries.
AstraZeneca remains proud of the role that Vaxzevria played in the global effort to end the pandemic and is committed to working with regulators in other countries to determine the best course of action for its commercial future. This is a developing story and updates will be provided as more information becomes available.
